White Paper: Flow Cytometry Advantages in Immunotherapy Clinical Trials
Our white paper takes an in-depth look at the world of flow cytometry. Nithianandan Selliah, Global Head of Flow Cytometry, and Ishita Modi, Director, Scientific Customer Solutions at Cerba Research, examine its unique benefits and future potential. They highlight the latest trends in technology and set out the key points to consider when planning a flow cytometry-based clinical trial and choosing a partner lab.
CerbACT Asia – Center of Excellence in Immuno-Oncology
CerbACT Asia empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research & clinical development strategies, combining the strengths of Cerba Research and ACT Genomics. We are enabled by cutting edge technologies in Flow Cytometry (FCM), Immunohistochemistry (IHC), and PBMC/cell isolations, while functioning as a central laboratory in the APAC region. Working with biotech, pharma, government and nongovernmental organizations, our team is ready to turn precision medicine into action!
Download the flyer to learn more on CerbACT Asia’s capabilities.
Webinar: Turning Precision Medicine into Action in Immuno-Oncology
The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.
In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.
- Jérôme Sallette, PhD, CSO Cerba Research
- Shu Jen Chen, PhD, CSO ACT Genomics
- Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
- George Wei, PhD, Vice President R&D ACT Genomics
- Renaud Burrer, PhD, Head of Histopathology Cerba Research
- Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research
Submit your information below to watch the webinar or to download the slide deck to receive our expert’s insights.
Webinar: The Advantages and Versatility of Flow Cytometry in Clinical Development
It is clear that the therapeutic future lies in biomarkers through the development of immunotherapies and companion diagnostics. Among the techniques of biomarker analysis, there is Flow Cytometry, which allows for precise analysis of liquid samples, but not only that.
Validation test development for specific biomarkers is a prerequisite for a successful application in translational research, preclinical and clinical phases. The advantages and disadvantages of this technique, the samples, the conditions of use: Cerba Research will open the doors of its worldwide laboratories for an hour. To answer all your questions about one of the leading technique of analysis for the development of innovative treatments, our experts will share their knowledge and experience.
Nithianandan Selliah, Ph.D. – Global Head of Flow Cytometry at Cerba Research
Nithianandan obtained his PhD in Immunology and started to work on HIV research. After more than 10 years of HIV research, he joined a biotech company to work on biomarker discovery for autoimmune diseases. His interest in Flow cytometry at the biotech led him to join global CRO to work on assay development and validation in Flow cytometry for global clinical trials. He joined Cerba Research to continue to work on his passion of Flow cytometry in clinical trials and takes on new challenges to build the best Flow cytometry service for the clients. He is working with exceptional scientific teams in the US and Belgium to bring on new assays for various therapeutic indications, including Immuno-oncology and autoimmune diseases.
Ishita Modi – Director, Scientific Customer Solutions at Cerba Research
A microbiologist by education, Ishita finished her studies at Gujarat University in India and moved on to starting her career in the United States. She has more than 15 years of experience in the clinical and diagnostic research industry. Her expertise is in building a strong foundation of clinical operations and clinical research with a commitment to meeting client’s scientific needs to help advance medicine. Ishita has worked at CRO/Central Lab as well as at some of the leading clinical diagnostic labs in the region. Her scientific expertise includes infectious diseases and genetics and gained extensive experience in microbiology, virology, and molecular biology. Ishita is a New York State certified Medical Technologist and also certified IRB (Institutional Review Board) professional. Her experience over the years has made her very strong in all aspects of clinical research and regulatory requirements. She has a passion for advancing science and making a difference in the future of healthcare.